MORGAN STANLEY PLC/CALL/MEDTRONIC/120/0.1/20.12.24 Share Price

Warrant

DE000MB8SLC0

Market Closed - Börse Stuttgart 17:07:05 28/06/2024 BST
0.043 EUR +2.38% Intraday chart for MORGAN STANLEY PLC/CALL/MEDTRONIC/120/0.1/20.12.24
Current month+72.00%
1 month+72.00%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes
Date Price Change
28/06/24 0.043 +2.38%
27/06/24 0.042 +2.44%
26/06/24 0.041 -2.38%
25/06/24 0.042 0.00%
24/06/24 0.042 -6.67%

Delayed Quote Börse Stuttgart

Last update June 28, 2024 at 05:07 pm

More quotes

Static data

Product typePlain-Vanilla-Warrants
Buy / SellCALL
Underlying MEDTRONIC PLC
Issuer Morgan Stanley
WKN MB8SLC
ISINDE000MB8SLC0
Date issued 14/07/2023
Strike 120 $
Maturity 20/12/2024 (175 Days)
Parity 10 : 1
Emission price 0.17
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 0.216
Lowest since issue 0.015
Spread 0.003
Spread %6.67%

Company Profile

Medtronic plc is one of the world leaders in designing, manufacturing and marketing of medical equipment. Net sales break down by sector of activity as follows: - general and minimally invasive surgery (28.8%): surgical equipment, intra-operative monitoring systems, ventilation systems, etc.; - cardiac rhythm management (18.6%): implantable cardiac pacemakers, implantable defibrillators and automatic external defibrillators, cardiac ablation probes, etc.; - vascular diseases and cardiac surgery (17.4%): coronary stents, endoprostheses for aortal pathologies, distal protection systems, catheters, heart valve prostheses, auto-transfusion equipment, cardiac ablation devices, etc.; - spinal disorders (14.1%): spinal prostheses, disc prostheses, cerebral stimulation systems, bone graft technologies and mini-invasive spinal surgery, etc. The group also develops medical imagery-guided surgical navigation systems activity; - neurovascular, ear, nose and throat (ENT) and pelvic diseases (8.2%); - diabetes management (7.4%): internal and external glycemia monitoring systems and insulin pumps; - neurological disorders (5.5%): neurostimulation and pumped medication administration products, diagnostic tools, etc. Net sales are distributed geographically as follows: Ireland (0.3%), the United States (50.9%) and other (48.8%).
Sector
-
More about the company

Ratings for Medtronic plc

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

Consensus: Medtronic plc

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
33
Last Close Price
78.71 USD
Average target price
94.02 USD
Spread / Average Target
+19.46%
Consensus